Breaking News

Financial Report: InterMune

February 22, 2013

Esbriet revenue up 204%


4Q Revenues: $8.2 million (earnings were $2.7 million in 4Q11)

4Q Loss: $58.6 million (loss of $44.5 million in 4Q11)

FY Revenues: $26.2 million (earnings were $5.4 million FY11)

FY Loss: $150.1 million (loss of $154.8 million FY11)

Comments: Esbriet (pirfenidone) revenue in the quarter was $8.2 million, up 204%. Results in the quarter included the effect of the approximate 11% German price decrease of Esbriet, which became effective September 15, 2012. Esbriet was approved in Canada October 1, 2012 for the treatment of mild to moderate IPF and became commercially available on January 2, 2013.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision